127852-78-2

Usage

Uses

Used in Pharmaceutical Industry:
Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-3-hydroxy-, (S)(9CI) is used as a building block for the synthesis of various drugs and compounds due to its unique structure and stereochemistry. Its specific (S)-configuration allows for targeted interactions with biological molecules, enhancing the efficacy and selectivity of the resulting pharmaceuticals.
Used in Drug Development:
Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-3-hydroxy-, (S)(9CI) is employed in drug development as a key component in the creation of new therapeutic agents. Its unique structure and stereochemistry enable the design of drugs with improved pharmacokinetic and pharmacodynamic properties, leading to more effective treatments for various diseases and conditions.
Used in Research:
Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-3-hydroxy-, (S)(9CI) is also used in research settings to study the interactions between amino acid derivatives and biological molecules. Understanding these interactions can provide valuable insights into the development of new drugs and therapeutic agents, as well as the underlying mechanisms of various diseases and conditions.

Upstream product

• 87554-49-2 (R)-(-)-methyl N-t-butyloxycarbonyl-3-hydroxy-4-aminobutanoate 
• 4530-20-5 BOC-glycine 
• 181772-51-0 ethyl (3R)-4-(tert-butyloxycarbonyl)amino-3-hydroxybutanoate 
• 847599-34-2 4-benzyloxy-1-tert-butyl-pyrrolidin-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 7013-05-0 (S)-4-amino-3-hydroxybutanoic acid 
• 924-49-2 DL-4-amino-3-hydroxybutyric acid 
• 119960-04-2 methyl 4-[(tert-butoxycarbonyl)amino]-3-oxobutanoate 
• 34619-03-9 tert-butyldicarbonate 

Relevant academic research and scientific papers

A paradigm for solvent and temperature induced conformational changes

The complex conformational dependency on environment of Boc-amine (see scheme) has been investigated. This model organic molecule has many features applicable to areas of chemistry, biology, physics, and computational chemistry. It is soluble in both non-polar and polar solvents, conformationally heterogeneous, and capable of supramolecular assembly. Copyright

HETEROCYCLIC GLP-1 AGONISTS

This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME

The present invention includes substituted 1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.

ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS

The present invention provides compounds of formula (I) wherein G1 is oxygen; R1 is hydrogen; R2 is group (P) L is a bond, methylene or ethylene; one of A1 and A2 is S, SO or SO2 and the other is -C(R4)R4-; R3 is hydrogen or methyl; each R4 is independently hydrogen or methyl; Y2 and Y3 are independently CH or nitrogen, wherein Y2 and Y3 are not both nitrogen; X2 is C-X6 or nitrogen; X1, X3 and X6 are independently hydrogen, halogen or trihalomethyl, wherein at least two of X1, X3 and X6 are not hydrogen; X4 is trifluoromethyl, difluoromethyl or chlorodifluoromethyl. The invention also provides intermediates useful for the preparation of compounds of formula (I), as well as methods of controlling insects, acarines, nematodes or molluscs using the compounds of formula (I).

DIHYDROPYRROLE DERIVATIVES AS INSECTICIDAL COMPOUNDS

The present invention provides compounds of formula (I), wherein G1 is oxygen; R1 is hydrogen; R2 is group P L is a bond, methylene or ethylene; one of A1 and A2 is S, SO or S02 and the other is -C(R4)R4- R3 is hydrogen or methyl; each R4 is independently hydrogen or methyl; Y1 is C-R6, CH or nitrogen; Y2 and Y3 are independently CH or nitrogen; wherein no more than two of Y1, Y2 and Y3 are nitrogen and wherein Y2 and Y3 are not both nitrogen; R5 is hydrogen, halogen, cyano, nitro, NH2, -C2alkyl, C3-C2haloalkyl, C3-C5cycloalkyl, C3- C5halocycloalkyl, C1-C2alkoxy, C1-C2haloalkoxy; R6 together with R5 forms a -CH=CH-CH=CH- bridge; X2 is C-X6 or nitrogen; X1, X3 and X6 are independently hydrogen, halogen or trihalomethyl, wherein at least two of X1, X3 and X6 are not hydrogen; X4 is trifluoromethyl, difluoromethyl or chlorodifluoromethyl. The invention also provides intermediates useful for the preparation of compounds of formula I, as well as methods of controlling insects, acarines, nematodes or molluscs using the compounds of formula I.

ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS

The present invention provides compounds of formula (I) wherein G1 is oxygen; R1 is hydrogen; R2 is group P, L is a bond, methylene or ethylene; one of A1 and A2 is S, SO or SO2 and the other is -C(R4)R4-; R3 is hydrogen or methyl; each R4 is independently hydrogen or methyl; Y1, Y2 and Y3 are independently CH or nitrogen; wherein no more than two of Y1, Y2 and Y3 are nitrogen and wherein Y2 and Y3 are not both nitrogen; R5 is chloro, bromo, fluoro; X2 is C-X6 or nitrogen; Χ1, Χ3 and X6 are independently hydrogen, halogen or trihalomethyl, wherein at least two of X1, X3 and X6 are not hydrogen; X4 is trifluoromethyl, difluoromethyl or chlorodifluoromethyl. The invention also relates to methods of using the compounds to control insects, acarines, nematodes or molluscs, as well as intermediates usefor the the sysnthesis of the compounds.

ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS

The present invention provides compounds of formula (I), wherein G1 is oxygen; R1 is hydrogen; R2 is group P (P) L is a bond, methylene or ethylene; one of A1 and A2 is S, SO or SO2 and the other is -C(R4)R4-R3 is hydrogen or methyl; each R4 is independently hydrogen or methyl; Y1 is C-R6, CH or nitrogen; Y2 and Y3 are independently CH or nitrogen; wherein no more than two of Y1, Y2 and Y3 are nitrogen and wherein Y2 and Y3 are not both nitrogen; R5 is hydrogen, halogen, cyano, nitro, NH2, C1-C2alkyl, C1-C2haloalkyl, C3-C5cycloalkyl, C3-C5halocycloalkyl, C1-C2alkoxy, C1-C2haloalkoxy; R6 together with R5 forms a -CH=CH-CH=CH- bridge; X2 is C-X6 or nitrogen; X1, X3 and X6 are independently hydrogen, halogen or trihalomethyl, wherein at least two of X1, X3 and X6 are not hydrogen; X4 is trifluoromethyl, difluoromethyl or chlorodifluoromethyl. The invention also provides intermediates useful for the preparation of compounds of formula (I), as well as methods of controlling insects, acarines, nematodes or molluscs using the compounds of formula (I).

Total synthesis of (+)-negamycin and its 5-epi-derivative

(+)-Negamycin was prepared in 13 steps in an overall yield of 31% from commercially available ethyl (R)-(+)-4-chloro-3-hydroxybutanoate. The key step in the reaction sequence was a highly stereoselective asymmetric Michael addition of chiral amine (-)-21

The synthesis of baclofen and GABOB via Rh(II) catalyzed intramolecular C-H insertion of α-diazoacetamides

The synthesis of baclofen and GABOB is reported via hydrolysis of the corresponding N-tert-butyl γ-lactams, which were obtained from Rh(II) catalyzed intramolecular C-H insertion of α-diazoacetamides.

Construction of three building blocks for the total synthesis of microsclerodermins

Three building blocks 2, 3, and 4 for the total synthesis of microsclerodermins (1) have been efficiently constructed from carboxylic acids 6, 14, and 20, respectively.